Literature DB >> 11204384

Minimally invasive direct access heart valve surgery.

J G Byrne1, M K Hsin, D H Adams, L Aklog, S F Aranki, G S Couper, R J Rizzo, L H Cohn.   

Abstract

We review our experience with minimally invasive direct access (MIDA) heart valve surgery in 518 patients. Two hundred fifty-two patients underwent MIDA aortic valve replacement (AVR) or repair and 266 underwent MIDA mitral valve repair or replacement. Among the 250 AVRs, 157 (63%) were men, aged 63.2 +/- 14.6 years, NYHA functional Class 2.4 +/- 0.8. The surgical approach was right parasternal in 36 (14%) or upper hemisternotomy in 216 (86%). There were four (2%) operative deaths. Perioperative complications included 14 (5.6%) reexplorations for bleeding, 7 (3%) chest wound infections, 5 (2%) strokes, and 1 (0.4%) external iliac vein injury. Follow-up was complete in 193 (77%) patients, with a mean follow-up of 12 +/- 8 months. Late complications included 2 (0.8%) nonfatal myocardial infarctions, 4 (2%) reoperations for, respectively, 2 pericardial complications, 1 paravalvar leak, and 1 infected valve. There were five (2%) late deaths from congestive heart failure, pneumonia, hemorrhage, aneurysm, and cancer. Mean follow-up NYHA Class was 1.4 +/- 0.6. For the 266 mitral patients, 145 (54.5%) were men, age 58.7 +/- 13.6 years, functional Class 2.3 +/- 0.5. The surgical approach was right parasternal in 195 (73%), lower hemisternotomy in 53 (20%), right submammary thoracotomy in 9 (3.4%), or full sternotomy through a small skin incision in 9 (3.4%). There were 2 (0.8%) operative deaths. Perioperative complications included 4 (1.5%) reoperations for bleeding, 4 (1.5%) strokes, and 5 (2%) wound infections, and 3 (1%) ascending aortic complications. Follow-up was complete in 202 (76%) patients with a mean follow-up of 9.5 +/- 6.4 months. Late complications included one (0.4%) nonfatal myocardial infarction and three (1%) reoperations all converting repairs to replacements. There were three (1%) late deaths from suicide, pneumonia, and sudden death, respectively. Mean follow-up NYHA functional Class was 1.3 +/- 0.5. We conclude that MIDA heart valve surgery is safe and effective for the majority of patients requiring isolated elective aortic or mitral valve surgery.

Entities:  

Mesh:

Year:  2000        PMID: 11204384     DOI: 10.1111/j.1540-8191.2000.tb00441.x

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  7 in total

1.  [Perioperative complications after heart valve replacement].

Authors:  U Rosendahl; I C Ennker; A Albert; S Bauer; A Mortasawi; K Bauer; F Dalladaku; J Bories; J Ennker
Journal:  Z Kardiol       Date:  2001-12

Review 2.  Anterolateral minithoracotomy versus median sternotomy for mitral valve disease: a meta-analysis.

Authors:  Chao Ding; Da-ming Jiang; Kai-yu Tao; Qun-jun Duan; Jie Li; Min-jian Kong; Zhong-hua Shen; Ai-qiang Dong
Journal:  J Zhejiang Univ Sci B       Date:  2014-06       Impact factor: 3.066

3.  Minimal access aortic root, valve, and complex ascending aortic surgery.

Authors:  J G Byrne; A N Karavas; L H Cohn; D H Adams
Journal:  Curr Cardiol Rep       Date:  2000-11       Impact factor: 2.931

4.  Combined PCI and minimally invasive heart valve surgery for high-risk patients.

Authors:  Ramanan Umakanthan; Marzia Leacche; Michael R Petracek; David X Zhao; John G Byrne
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-12

5.  Minimally invasive approaches versus conventional sternotomy for aortic valve replacement: a propensity score matching study.

Authors:  Ji Hyun Bang; Jong Wook Kim; Jae Won Lee; Joon Bum Kim; Sung-Ho Jung; Suk Jung Choo; Cheol Hyun Chung
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2012-04-03

6.  Reversed L-type Upper Partial Sternotomy in Aortic Valve Replacement: an Initial Experience.

Authors:  Alen Karic
Journal:  Med Arch       Date:  2016-05-31

7.  Aortic Root Replacement via Lower Hemisternotomy After an Esophageal Operation.

Authors:  Kazuhiko Uwabe; Noriyasu Masuda
Journal:  Ann Vasc Dis       Date:  2021-12-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.